BioCatalystWatch
ANLWorkspace / ANL / OverviewCompany library
Price
Market cap
Next catalystExpected 2H 2026AN4005 · Phase 1 dataSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

AN9025

Small molecule

pan-RAS(ON) × KRAS

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

AN4005

Small molecule

PD-L1

PreINDP1P2P3FilingApproved
Upcoming / outlook

palupiprant (AN0025)

Small molecule

EP4

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

AN4035

CEACAM5

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

AN8025

PD-L1 × CTLA-4 × CD28

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

AN4005

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

AN4005

Small molecule

PD-L1

PreINDP1P2P3FilingApproved
Upcoming / outlook

AN8025

PD-L1 × CTLA-4 × CD28

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

palupiprant (AN0025)

Small molecule

EP4

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

AN9025

Small molecule

pan-RAS(ON) × KRAS

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

AN4035

CEACAM5

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Other pipelines

palupiprant (AN0025)

Small molecule

EP4

PreINDP1P2P3FilingApproved

Pelareorep (AN1004)

Oncolytic virus

PreINDP1P2P3FilingApproved

Partner / License out

TNFR2

PreINDP1P2P3FilingApproved

Financial position

Cash and cash equivalents

Source and basis

Short-term investments

Source and basis

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Shares outstanding

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ANL PR & News

PR & News

ANL SEC archive